Rubicon Research Limited Successfully Raises ₹1,377.5 Crore in IPO

Rubicon Research Limited has successfully completed its Initial Public Offering (IPO), raising a total of ₹1,377.5 crore. This significant fundraising effort comprised both a fresh issue of shares, injecting capital directly into the company, and an offer for sale, allowing existing shareholder General Atlantic Singapore RR Pte. Ltd. to divest some of its stake. Rubicon Research, headquartered in Mumbai, is a pharmaceutical formulations company focused on creating, producing, and marketing specialized branded products for other pharmaceutical firms. Legal advice for Rubicon Research was provided by AZB & Partners, while Khaitan & Co advised the Book Running Lead Managers, which included Axis Capital Limited, IIFL Capital Services Limited, JM Financial Limited, and SBI Capital Markets Limited.

Impact: An IPO typically signifies a company's transition to becoming publicly traded, offering greater liquidity for investors and access to capital for growth. For Rubicon Research, this IPO provides capital for expansion, R&D, or debt reduction, potentially enhancing its market position. Investors gain an opportunity to invest in a pharmaceutical formulations company with a specialization in branded products. Rating: 7/10

Difficult Terms: - Initial Public Offering (IPO): The process by which a private company first sells shares of stock to the public, becoming a publicly traded entity. - Fresh Issue: Issuance of new shares by a company to raise capital. - Offer for Sale (OFS): Existing shareholders sell their shares to new investors; the company does not receive any funds from this part. - Promoter: The person or entity that founded or controls the company. - Pharmaceutical Formulations: The process of converting active pharmaceutical ingredients (APIs) into a finished dosage form (like tablets, capsules, syrups) suitable for administration to patients. - Book Running Lead Managers (BRLMs): Investment banks that manage the IPO process, underwrite the issue, and market it to investors.